Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
Antiangiogenic drugs targeting the VEGF pathway have slowed metastatic disease
progression in some patients, leading to progression-free survival (PFS) and overall survival …
progression in some patients, leading to progression-free survival (PFS) and overall survival …
Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010
OBJECTIVES: Recent literature has highlighted histological types of ovarian carcinoma as
distinct diseases, each with unique clinical and molecular features. Historically, the …
distinct diseases, each with unique clinical and molecular features. Historically, the …
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a …
Background In the international randomised phase 3 CORRECT trial (NCT01103323),
regorafenib significantly improved overall survival versus placebo in patients with treatment …
regorafenib significantly improved overall survival versus placebo in patients with treatment …
Systemic therapy for non–clear cell renal cell carcinomas: a systematic review and meta-analysis
Context Clinical data supporting the use of targeted agents for the treatment of metastatic
renal cell carcinoma (RCC) are based predominantly on patients with clear cell histology …
renal cell carcinoma (RCC) are based predominantly on patients with clear cell histology …
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a …
J Garcia-Donas, E Esteban, LJ Leandro-García… - The lancet …, 2011 - thelancet.com
Background Sunitinib is a tyrosine kinase inhibitor with proven efficacy in renal-cell
carcinoma, but some patients do not respond or need dose reductions due to toxicity …
carcinoma, but some patients do not respond or need dose reductions due to toxicity …
[HTML][HTML] Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors
M Schmidinger - European Journal of Cancer Supplements, 2013 - Elsevier
Vascular-endothelial growth-factor (receptor)(VEGF)(R)-inhibiting agents–sunitinib [1],[2],[3],
sorafenib [4],[5], pazopanib [2],[6], bevacizumab [7],[8], axitinib [5] and tivozanib [9],[10]–have …
sorafenib [4],[5], pazopanib [2],[6], bevacizumab [7],[8], axitinib [5] and tivozanib [9],[10]–have …
[HTML][HTML] RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell …
JL Lee, MK Kim, I Park, JH Ahn, DH Lee, HM Ryoo… - Annals of oncology, 2015 - Elsevier
Background The standard sunitinib schedule, 4 weeks on, followed by 2 weeks off (4/2
schedule), is associated with troublesome toxicities, and maintenance of adequate sunitinib …
schedule), is associated with troublesome toxicities, and maintenance of adequate sunitinib …
[HTML][HTML] A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study
JH Yi, S Thongprasert, J Lee, DC Doval… - European Journal of …, 2012 - Elsevier
BACKGROUND: Biliary tract carcinoma (BTC) is rare in the West, but not uncommon in Asia
and is a highly fatal malignancy. VEGF expression is related with poor outcome in patients …
and is a highly fatal malignancy. VEGF expression is related with poor outcome in patients …
Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell …
Y Tomita, H Uemura, H Fujimoto, H Kanayama… - European journal of …, 2011 - Elsevier
BACKGROUND: Axitinib (AG-013736) is an oral, selective and potent inhibitor of vascular
endothelial growth factor receptors (VEGFR)-1, 2 and 3. This phase II study investigated …
endothelial growth factor receptors (VEGFR)-1, 2 and 3. This phase II study investigated …
[HTML][HTML] Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors
T Terada, S Noda, K Inui - Pharmacology & therapeutics, 2015 - Elsevier
Molecular-targeted therapies with tyrosine kinase inhibitors (TKIs) have provided a major
breakthrough in cancer treatment. These agents are given orally and demonstrated to be …
breakthrough in cancer treatment. These agents are given orally and demonstrated to be …